Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
Background/Aims: Hodgkin Lymphoma (HL) has become one of the most treatable cancers, with more than 80% patients in the advanced stage being cured through improvement of therapeutic regimens. Nevertheless, some treatments were accompanied with toxicities.Methods: In the current study, a network meta...
Guardado en:
Autores principales: | Fajun Pei, Yang Yu, Bin Dong, Hui Guan, Xinzhe Dong, Fen Zhao |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bf77a664bda34765b159ad5a49981c0e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
por: Pezzullo Luca, et al.
Publicado: (2021) -
COMPLEX ESTIMATION OF BRONCHOPULMONARY SYSTEM IN PATIENTS WITH HODGKINS LYMPHOMA
por: Yu. N. Obgolts, et al.
Publicado: (2012) -
Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
por: Jezeršek Novaković B, et al.
Publicado: (2021) -
Analysis of mortality at non-Hodgkin lymphomas in the unit of cancer chemotherapy of Irkutsk Regional Oncologic Dispensary in 2011-2013
por: E. V. Zubkova, et al.
Publicado: (2014) -
Hodgkin lymphoma. ASCO, EHA and ASH 2020 news
por: Elena A. Demina
Publicado: (2021)